World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
World Lung 2025 – backing for Bristol’s pivotal HER3 conjugate moves
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
World Lung 2025 preview – best of the rest
Posters and mini-orals include another VEGF bispecific.
World Lung 2025 preview – late-breakers in focus
Summit and Nuvalent have scored prized plenary spots.
Lunsumio steps into Columvi territory
Sunmo succeeds in a setting very similar to Starglo's.
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
EHA 2025 – Incyte puts its foot on the CALR gas
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
EHA 2025 – ELVN-001 enlivens investors
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
ASCO 2025 movers – bispecifics to the rescue
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
